Cannabinoid Composition Modulating IL-6 and COX via Precursor Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis, using cannabinoids do not effectively utilize specific combinations of cannabinoids and their precursor acids, which are shown to modulate immune cell activity and reduce IL-6 secretion and COX expression.
Innovation Solution
A composition comprising specific ratios of cannabidiol (CBD), cannabidiolic acid (CBDA), tetrahydrocannabinol (THC), and tetrahydrocannabinol acid (THCA), along with additional compounds like cannabigerol (CBG), apigenin, beta caryophyllene (BCP), and β myrcene, is used to inhibit IL-6 secretion and reduce COX expression, offering therapeutic benefits for IL-6-related and COX-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If specific combinations and ratios of cannabinoids and their precursor acids are used, then therapeutic effectiveness for inflammatory diseases is improved, but prior art did not describe or suggest such specific combinations
Solution Approach 1:
The patent combines multiple cannabinoids (CBD, THC) with their respective precursor acids (CBDA, THCA) in specific weight ratios to create a synergistic composition. This merging of compounds addresses the limitation of prior art that used single cannabinoids or undefined mixtures, thereby improving therapeutic effectiveness for inflammatory diseases while establishing a defined composition structure.
Solution Approach 2:
The patent specifies precise weight ratios (CBD:CBDA = 1:2 to 2:1, THC:THCA = 1:1 to 4:1, and (CBD+CBDA):(THC+THCA) = 1:2 to 2:1) to optimize therapeutic effect. By controlling these compositional parameters, the invention transforms the undefined mixture problem into a precisely formulated composition, resolving the contradiction between effectiveness and complexity through defined specifications.
2Reliability
If cannabinoids are used to treat inflammatory diseases, then immune cell activity is modulated and IL-6 secretion is reduced, but the mechanism of action requires specific composition ratios for optimal effect
Solution Approach 1:
The patent establishes specific weight ratio parameters for cannabinoids and precursor acids to optimize immune modulation efficacy. By defining these compositional parameters, the invention ensures consistent therapeutic effect while providing clear manufacturing specifications, thus resolving the contradiction between efficacy reliability and manufacturing precision requirements.
3Reliability
If prior art used single cannabinoids or undefined mixtures, then treatment approaches were simple, but therapeutic effectiveness was insufficient compared to specific cannabinoid combinations
Solution Approach 1:
The patent merges multiple cannabinoids and precursor acids into a unified composition with defined ratios, creating a synergistic treatment approach. This combination strategy improves therapeutic effectiveness beyond what single cannabinoids or undefined mixtures could achieve, while the defined structure prevents the treatment from becoming overly complex or unpredictable.
Data Source
AI summary
The present invention is directed to a composition including a cannabinoid and its acid precursor, and optionally further includes a terpene and/or a flavonoid. Further provided are methods of using the composition, such as for inhibiting IL-6 secretion, and for treating a subject afflicted with an IL-6-related disease, a COX-related disease, or both.